{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:55:34Z","timestamp":1794858934085,"version":"4.9.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment of complicated infections in persons who inject drugs (PWID) and patients experiencing homelessness poses a unique challenge to clinicians. Long-acting lipoglycopeptide antibiotics, such as oritavancin, may facilitate extended courses of outpatient intravenous therapy while avoiding the need for central lines, improving compliance and thus increasing the chance of clinical cure.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective chart review of adult PWID who received at least one dose of oritavancin for a gram-positive infection between 1\/1\/17 and 6\/30\/19 at a large safety net hospital.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty three PWID received 24 courses of at least one dose of oritavancin for a gram-positive infection; 16 were experiencing homelessness at the time of diagnosis. Methicillin resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) was the most common infecting pathogen and bone or joint the most frequent infection site. Nineteen encounters resulted in clinical cure, including 5 whose conditions improved despite non-adherence to their prescribed regimen. Three patients experienced a non-favorable outcome. Two patients experienced mild adverse drug reactions that did not interfere with therapy; no patients died while on therapy.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Oritavancin may be a clinically effective treatment option for the management of complicated gram-positive infections in PWID and patients experiencing homelessness. Further studies should be performed to validate these results.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-020-00452-z","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T13:03:06Z","timestamp":1603890186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs"],"prefix":"10.1186","volume":"21","author":[{"given":"Aileen","family":"Ahiskali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0480-5829","authenticated-orcid":false,"given":"Heather","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"452_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1086\/313703","volume":"30","author":"IA Binswanger","year":"2000","unstructured":"Binswanger IA, Kral AH, Blumenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000;30:579\u201381. \n                  https:\/\/doi.org\/10.1086\/313703\n                  \n                .","journal-title":"Clin Infect Dis"},{"key":"452_CR2","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/j.1360-0443.1997.tb02853.x","volume":"92","author":"A Morrison","year":"1997","unstructured":"Morrison A, Elliott L, Gruer L. Injecting-related harm and treatment-seeking behaviour among injecting drug users. Addiction. 1997;92:1349\u201352.","journal-title":"Addiction."},{"issue":"2","key":"452_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/00952991003592311","volume":"36","author":"KT Phillips","year":"2010","unstructured":"Phillips KT, Stein MD. Risk practices associated with bacterial infections among injection drug users in Denver, CO. Am J Alcohol Abuse. 2010;36(2):92\u20137. \n                  https:\/\/doi.org\/10.3109\/00952991003592311\n                  \n                .","journal-title":"Am J Alcohol Abuse"},{"issue":"7","key":"452_CR4","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/cid\/ciy632","volume":"68","author":"AC Miller","year":"2019","unstructured":"Miller AC, Polgreen PM. Many opportunities to record, diagnose, or treat injection-drug related infections are missed: a population-based cohort study of inpatient and emergency department settings. Clin Infect Dis. 2019;68(7):1166\u201375. \n                  https:\/\/doi.org\/10.1093\/cid\/ciy632\n                  \n                .","journal-title":"Clin Infect Dis"},{"issue":"4","key":"452_CR5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/BF02344031","volume":"77","author":"JY Song","year":"2000","unstructured":"Song JY, Safaeian M, Strathdee SA, Vlahov D, Celentano DD. The prevalence of homelessness among injection drug users with and without HIV infection. J Urban Health. 2000;77(4):678\u201387. \n                  https:\/\/doi.org\/10.1007\/BF02344031\n                  \n                .","journal-title":"J Urban Health"},{"issue":"3","key":"452_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.drugalcdep.2013.03.009","volume":"132","author":"SL Linton","year":"2013","unstructured":"Linton SL, Celentano DD, Kirk GD, Mehta SH. The longitudinal association between homelessness, injection drug use, and injection-related risk behavior among persons with a history of injection drug use in Baltimore, MD. Drug Alcohol Depend. 2013;132(3):457\u201365. \n                  https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.03.009\n                  \n                .","journal-title":"Drug Alcohol Depend"},{"key":"452_CR7","doi-asserted-by":"publisher","first-page":"ofx102","DOI":"10.1093\/ofid\/ofx102","volume":"4","author":"DJ Buehrle","year":"2017","unstructured":"Buehrle DJ, Shields RK, Shah N, Shoff C, Sheridan K. Risk factors associated with outpatient parenteral antibiotic therapy program failure among intravenous drug users. Open Forum Infect Dis. 2017;4:ofx102. \n                  https:\/\/doi.org\/10.1093\/ofid\/ofx102\n                  \n                .","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"452_CR8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/cid\/ciy722","volume":"68","author":"EF Eaton","year":"2019","unstructured":"Eaton EF, Matthew RE, Lane PS, et al. A 9-point risk assessment for patients who inject drugs and require intravenous antibiotics: focusing inpatient resources on patients at greatest risk of ongoing drug use. Clin Infect Dis. 2019;68(6):1041\u20133. \n                  https:\/\/doi.org\/10.1093\/cid\/ciy722\n                  \n                .","journal-title":"Clin Infect Dis"},{"key":"452_CR9","volume-title":"Orbactiv (Oritavancin) injection","author":"Product information","year":"2019","unstructured":"Product information. Orbactiv (Oritavancin) injection. Lincolnshire: Melinta Therapeutics; 2019."},{"issue":"5","key":"452_CR10","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1128\/AAC.03029-15","volume":"60","author":"RN Jones","year":"2016","unstructured":"Jones RN, Moeck G, Arhin FF, Dudley MN, Rhomberg PR, Mendes RE. Results from oritavancin resistance surveillance programs (2011 to 2014): clarification for using vancomycin as a surrogate to infer oritavancin susceptibility. Antimicrob Agents Chemother. 2016;60(5):3174\u20137. \n                  https:\/\/doi.org\/10.1128\/AAC.03029-15\n                  \n                .","journal-title":"Antimicrob Agents Chemother"},{"key":"452_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"452_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","volume":"6","author":"CL Stewart","year":"2017","unstructured":"Stewart CL, Turner MS, Frens JJ, Snider CB, Smith JR. Real-world experience with oritavancin therapy in invasive gram-positive infections. Infect Dis Ther. 2017;6:277\u201389. \n                  https:\/\/doi.org\/10.1007\/s40121-017-0156-z\n                  \n                .","journal-title":"Infect Dis Ther"},{"issue":"suppl 1","key":"452_CR13","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1007\/s40801-020-00192-w","volume":"7","author":"LE Brownell","year":"2020","unstructured":"Brownell LE, Adamsick ML, McCreary E, et al. Clinical outcomes and economic impact of oritavancin for gram-positive infections: a single academic medical center health system experience. Drugs \u2013 Real World Outcomes. 2020;7(suppl 1):S13\u20139.","journal-title":"Drugs \u2013 Real World Outcomes"},{"issue":"7","key":"452_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofz274","volume":"6","author":"T Morrisette","year":"2019","unstructured":"Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. Long-acting lipoglycopeptides: \u201clineless antibiotics\u201d for serious infections in persons you use drugs. Open Forum Infect Dis. 2019;6(7):1\u20137. \n                  https:\/\/doi.org\/10.1093\/ofid\/ofz274\n                  \n                .","journal-title":"Open Forum Infect Dis"},{"key":"452_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","volume":"8","author":"JT Bork","year":"2019","unstructured":"Bork JT, Heil EL, Berry S, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections. Infect Dis Ther. 2019;8:171\u201384. \n                  https:\/\/doi.org\/10.1007\/s40121-019-0247-0\n                  \n                .","journal-title":"Infect Dis Ther"},{"issue":"2","key":"452_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofz028","volume":"6","author":"C Bryson-Cahn","year":"2019","unstructured":"Bryson-Cahn C, Beieler AM, Chan JD, Harrington RD, Dhanireddy S. Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population. Open Forum Infect Dis. 2019;6(2):1\u20134. \n                  https:\/\/doi.org\/10.1093\/ofid\/ofz028\n                  \n                .","journal-title":"Open Forum Infect Dis"},{"key":"452_CR17","volume-title":"Dalvance (Dalbavancin) injection","author":"Product information","year":"2018","unstructured":"Product information. Dalvance (Dalbavancin) injection. Madison: Allergan USA, Inc.; 2018."}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00452-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-020-00452-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00452-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T05:25:03Z","timestamp":1604035503000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-00452-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-00452-z","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,28]]},"assertion":[{"value":"13 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved by the Hennepin Healthcare Research Institute, study # 19\u20134633.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"On behalf of both authors, the corresponding author states that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}